+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 28 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
O

Actively Recruiting

Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.

Age: 50Years +All GendersPhase 3
566 locations
E

Actively Recruiting

Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.

Age: 18Years +All GendersPhase 3
671 locations
C

Actively Recruiting

Researchers are evaluating how well zenagamtide works and how safe it is compared to insulin glargine in people with type 2 diabetes who have a higher risk of heart and blood vessel problems. This study includes participants already taking 1 to 3 diabetes medications and aims to see if zenagamtide is not worse than insulin glargine in controlling blood sugar levels over one year. Participants are randomly assigned to receive either zenagamtide or insulin glargine. Zenagamtide is given once weekly as an injection under the skin in the thigh, abdomen, or upper arm using a pre-filled pen injector. Insulin glargine is given once daily as a subcutaneous injection in the same body areas, with rotation of the injection site. The study lasts for at least 52 weeks for primary outcomes, with cardiovascular events monitored for 104 weeks or more. During the study, participants will have regular assessments including blood tests for HbA1c, body weight measurements, waist circumference, blood pressure, cholesterol levels, and markers of inflammation. The main measure is the change in blood sugar control after 52 weeks. The study also tracks heart-related events and other health changes over two years. Participants will be monitored closely throughout the study period to evaluate safety and treatment effects.

Age: 45Years +All GendersPhase 3
330 locations
E

Actively Recruiting

This research aims to explore the added benefits of deep, slow breathing exercises and suboccipital relaxation, alongside routine physiotherapy and rehabilitation, on autonomic, motor, cognitive, and emotional functions in people who have experienced a stroke. The study compares these combined approaches to routine physiotherapy alone, addressing a gap in current stroke rehabilitation methods. It seeks to provide new scientific evidence to improve recovery and reduce the impact of stroke globally. Participants are divided into three groups one group performs deep breathing exercises in addition to standard rehabilitation, another receives suboccipital relaxation alongside routine therapy, and a control group receives only the routine physiotherapy program. Both interventions last 6 weeks, with sessions three times per week. Deep breathing sessions involve guided breathing cycles while lying down, and suboccipital release includes a hands-on technique performed by a practitioner. The routine program includes gait, balance, and upper limb training. Throughout the study, participants will undergo assessments before and after the 6-week intervention period. These include measurements of heart rate variability, balance, motor activity, upper limb function, cognitive ability, and depression levels. The study monitors these outcomes to evaluate the effects of the interventions, with safety and adherence overseen by the research team. The total participation time corresponds to the 6-week intervention duration.

Age: 18Years - 84YearsAll GendersPhase Not Applicable
1 location
C

Actively Recruiting

Carpal tunnel syndrome CTS is a common nerve compression condition causing numbness, tingling, muscle weakness, and hand atrophy. This research aims to compare the effects of rest splints and high-intensity laser therapy HILT combined with physical therapy programs on pain, function, nerve conduction, and grip strength for patients with CTS. The study is designed as a prospective randomized controlled trial to better understand these treatments impacts on CTS symptoms and nerve function. Participants are divided into three groups. The first group receives a physical therapy program including wrist range of motion, strengthening, stretching, desensitization, tendon and nerve gliding exercises, and use of a resting splint for 6 weeks, five days a week 30 sessions total. The second group receives the same physical therapy plus high-intensity laser therapy over the carpal tunnel region daily for 6 weeks. The third group also follows the physical therapy program but receives a sham laser treatment mimicking the HILT without active laser emission to serve as a control. During the study, participants undergo assessments at baseline, after 6 weeks of treatment, and again at 12 weeks to measure pain using a Visual Analog Scale and other outcomes like function, sleep quality, neuropathic pain, nerve conduction studies, and grip strength. These evaluations include questionnaires, nerve tests, and strength measurements. The trial monitors participants progress and treatment effects over time to determine the comparative benefits of rest splints and HILT when combined with physical therapy.

Age: 18Years - 75YearsAll GendersPhase Not Applicable
2 locations
C

Actively Recruiting

Carpal tunnel syndrome CTS is the most common type of nerve compression disorder, causing symptoms like numbness, tingling, pain, and weakness in the hand areas served by the median nerve. This research compares two treatments for people with mild to severe CTS an ultrasound-guided injection around the median nerve and a traditional minimal incision surgery to relieve pressure on the nerve. The study aims to evaluate which approach better reduces symptoms and improves hand function. The study involves two treatment groups. One group will receive a minimal incision surgery where a small cut is made to relieve pressure on the median nerve by cutting the surrounding tissue. The other group will have an ultrasound-guided injection of 5 cc of 5% dextrose around the median nerve using a precise technique to reduce risk of injury. Both treatments target the same nerve but use different methods to reduce compression. Participants will be monitored throughout the study with assessments of wrist pain using a visual analog scale VAS at 4 and 12 weeks after treatment. Additional measurements include symptom questionnaires, nerve size by ultrasound, electrical nerve tests, and hand grip strength at the same time points. The study will track changes from baseline to understand each treatments impact on symptoms and nerve function over about three months.

Age: 18Years - 75YearsAll GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations

1-10 of 28

1